Clostridium Difficile News and Research

RSS

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Biota Holdings Limited advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).

10 Jun 2011

Quest Diagnostics receives MDEA gold award for Simplexa/3M technology

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa molecular diagnostic test on the 3M Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday in New York City.

From Quest Diagnostics 10 Jun 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.

3 Jun 2011

Scientists develop carbohydrate-based vaccine against C. difficile infection

There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.

31 May 2011

Some Veterans' health jeopardized due to poor infection control

Herman Williams came home safely after fighting in the jungles of Vietnam as a Marine. He was shocked to learn four decades later that his military service had again placed him in jeopardy — this time, because he got a tooth pulled. Williams is among 13,000 U.S. veterans who have been warned in the last two years that their blood should be tested for potentially fatal infections after possible exposures by improper hygiene practices at five VA hospitals in Ohio, Florida, Georgia, Missouri and Tennessee.

31 May 2011

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

The U.S. Food and Drug Administration today approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea.

30 May 2011

Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteria

Just like intelligence agents watching for the real terrorists threatening to attack, monitoring healthcare worker adherence to mandatory hand-washing protocols via hand-washing squads in hospitals can go a long way to stop outbreaks of the opportunistic C. diff bacteria, says Irena Kenneley, an infection prevention and control expert and assistant professor of nursing from the Frances Payne Bolton School of Nursing at Case Western Reserve University.

20 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

Gut bacteria influences brain chemistry and behaviour: Research

For the first time, researchers at McMaster University have conclusive evidence that bacteria residing in the gut influence brain chemistry and behaviour.

18 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.

11 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011

3M introduces Clean-Trace Hygiene Management System for healthcare facilities

As part of its effort to offer a wide range of environmental hygiene solutions for healthcare facilities, 3M Infection Prevention today announced its 3M™ Clean-Trace™ Hygiene Management System. This solution is designed to help hospitals assess the cleanliness of a surface and validate the efficacy of cleaning protocols and worker performance in less than one minute

11 May 2011

FDA clears Meridian's new C. difficile immunoassay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new Clostridium difficile immunoassay named Premier C. difficile GDH.

11 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Spotlight on the NDM-1 “superbug” highlights the long-standing but increasingly alarming situation of antibiotic resistance globally

At the world’s largest conference on infectious diseases – the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) which opens today – a special Symposium on NMD-1 (New Delhi metallo-beta-lactamase) will focus on the implications of the increasing detection of this gene, which makes bacteria highly resistant to almost all known antibiotics. This is part of an alarming trend of antibiotic resistance that threatens to turn back the clock on years of progress following the discovery of antimicrobials, which revolutionised human health globally.

6 May 2011

Quest Diagnostics' Simplexa C. difficile test is now available in Europe

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability in Europe of the Simplexa C. difficile Universal Direct test on the 3M Integrated Cycler.

From Quest Diagnostics 6 May 2011

Fecal transplant procedures performed at Sinai Hospital

Sudhir Dutta, M.D., head of the Division of Gastroenterology at Sinai Hospital, performed fecal transplant procedures for two patients with severe clostridium difficile (C. difficile) colitis that did not respond to routine antibiotic and other treatments. C. difficile causes symptoms ranging from mild diarrhea to more serious, sometimes life threatening colon inflammation.

5 May 2011

Clostridium Difficile News and Research

Further Reading

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Quest Diagnostics receives MDEA gold award for Simplexa/3M technology

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Scientists develop carbohydrate-based vaccine against C. difficile infection

Some Veterans' health jeopardized due to poor infection control

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Monitoring adherence to mandatory hand-washing protocols can help stop outbreaks of C. diff bacteria

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

Gut bacteria influences brain chemistry and behaviour: Research

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

3M introduces Clean-Trace Hygiene Management System for healthcare facilities

FDA clears Meridian's new C. difficile immunoassay

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Spotlight on the NDM-1 “superbug” highlights the long-standing but increasingly alarming situation of antibiotic resistance globally

Quest Diagnostics' Simplexa C. difficile test is now available in Europe

Fecal transplant procedures performed at Sinai Hospital

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News